Neurocrine Q1: INGREZZA $545M (+8%), CRENESSITY $14.5M; GAAP EPS $0.08; reaffirms FY25 guide

NEUROCRINE BIOSCIENCES INC

2025-Q1 EPS reported $0.08 revenue$572,600,000

INGREZZA net product sales $545M in Q1 2025, up 8% YoY; CRENESSITY sales $14.5M with 413 patient enrollment forms.
GAAP net income $7.9M ($0.08 EPS) vs $43.4M ($0.42) YoY; Non-GAAP net income $71.5M ($0.70) vs $124.8M ($1.20).
Reaffirmed 2025 INGREZZA net sales guidance of $2.5-$2.6B; total R&D guidance $960M-$1.01B GAAP.
Initiated Phase 3 registrational programs for osavampator in MDD and NBI-568 in schizophrenia.
Appointed Sanjay Keswani, M.D., as Chief Medical Officer effective June 2, 2025; authorized $500M share repurchase, $150M completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.